Our Services
Medical Information
Helpful Resources
Published on: 9/14/2026
Most common Vyvanse side effects, such as decreased appetite, dry mouth, trouble sleeping, headache, and jitteriness, tend to appear within the first days of starting the medication and often ease over roughly 1 to 4 weeks as your body adjusts. Because Vyvanse is long acting, day-to-day effects generally last around 10 to 14 hours after each dose, with some people noticing irritability or fatigue as it wears off in the evening. Side effects that persist beyond the first month, worsen, or involve chest pain, a racing heartbeat, fainting, severe mood changes, or significant weight loss are not something to wait out and should prompt a call to your prescriber. Timing varies widely based on your dose, how recently it changed, your age, other medications, sleep, and hydration, so there are several important factors to consider before assuming your symptoms are just normal adjustment. See below for the complete answer, including what typically resolves on its own, what usually does not, and when a dose adjustment may be needed.
If you are unsure whether what you are feeling is a temporary adjustment period, a dosing issue, or something unrelated to your medication that deserves attention, you do not have to guess in the meantime. A free, instant, online symptom check asks targeted questions about your symptoms, their timing, and your health history, then helps you understand possible explanations and how urgently to act. It takes only a few minutes, requires no insurance or appointment, and gives you a clearer, organized picture to bring to your prescriber so your next conversation is faster and more productive.
Last reviewed for medical accuracy: 09/14/2026
Vyvanse (lisdexamfetamine) is a commonly prescribed stimulant for attention-deficit/hyperactivity disorder (ADHD) and, in some cases, binge eating disorder. Like all medications, it can cause side effects—most of which are mild to moderate and often temporary. This guide explains how long these side effects typically last, what you can expect day by day, and when to reach out for medical advice.
Vyvanse is a prodrug that converts to dextroamphetamine in the body, producing gradual and sustained effects over about 10–14 hours. As your system adjusts, side effects may appear as your brain chemistry and metabolism adapt to the medication.
Most people experience side effects within the first few doses. For many, these ease up within days to weeks. Below is a breakdown of common side effects and their usual timelines:
Appetite Suppression
Insomnia or Sleep Disturbance
Dry Mouth
Headache
Stomachache or Nausea
Irritability or Mood Swings
Individual responses vary. Some may adjust within days, while others take several weeks. If side effects continue beyond a month or significantly interfere with daily life, it’s important to review your dose or timing with your doctor.
Most Vyvanse side effects are mild and short-lived, but contact your healthcare provider or seek emergency help if you experience:
For any life-threatening or serious concerns, always call emergency services or go to your nearest emergency department.
If you’re unsure whether your symptoms are related to Vyvanse or something else, consider a quick, free, online symptom check, using the doctor approved Ubie Symptom Checker to help clarify next steps and prepare for a conversation with your provider.
Vyvanse can be an effective part of ADHD or binge eating disorder treatment. While side effects are common at first, they usually decrease over days to weeks as your body adapts. Close communication with your doctor ensures that dosing and timing are optimized for both effectiveness and comfort.
Always speak to your doctor about any side effects that are severe, persistent, or concerning. If you experience anything life-threatening or serious, seek medical help immediately.
(References)
* Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present--a pharmacological and clinical perspective. J Psychopharmacol. 2013 Jun;27(6):479-96. doi: 10.1177/0269881113482532. Epub 2013 Mar 28. PMID: 23539642; PMCID: PMC3666194.
* Coghill DR, Caballero B, Sorooshian S, Civil R. A systematic review of the safety of lisdexamfetamine dimesylate. CNS Drugs. 2014 Jun;28(6):497-511. doi: 10.1007/s40263-014-0166-2. PMID: 24788672; PMCID: PMC4057639.
* Buoli M, Serati M, Cahn W. Alternative pharmacological strategies for adult ADHD treatment: a systematic review. Expert Rev Neurother. 2016;16(2):131-44. doi: 10.1586/14737175.2016.1135735. Epub 2016 Jan 14. PMID: 26693882.
* Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018 Sep;5(9):727-738. doi: 10.1016/S2215-0366(18)30269-4. Epub 2018 Aug 7. PMID: 30097390; PMCID: PMC6109107.
* Elliott J, Johnston A, Husereau D, Kelly SE, Eagles C, Charach A, Hsieh SC, Bai Z, Hossain A, Skidmore B, Tsakonas E, Chojecki D, Mamdani M, Wells GA. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis. PLoS One. 2020;15(10):e0240584. doi: 10.1371/journal.pone.0240584. Epub 2020 Oct 21. PMID: 33085721; PMCID: PMC7577505.
* Nanda A, Janga LSN, Sambe HG, Yasir M, Man RK, Gogikar A, Mohammed L. Adverse Effects of Stimulant Interventions for Attention Deficit Hyperactivity Disorder (ADHD): A Comprehensive Systematic Review. Cureus. 2023 Sep;15(9):e45995. doi: 10.7759/cureus.45995. Epub 2023 Sep 26. PMID: 37900465; PMCID: PMC10601982.
* Van Vyve L, Dierckx B, Lim CG, Danckaerts M, Koch BCP, Häge A, Banaschewski T. Pharmacotherapy for ADHD in children and adolescents: A summary and overview of different European guidelines. Eur J Pediatr. 2024 Mar;183(3):1047-1056. doi: 10.1007/s00431-023-05370-w. Epub 2023 Dec 14. PMID: 38095716.
* Scoten O, Tabi K, Paquette V, Carrion P, Ryan D, Radonjic NV, Whitham EA, Hippman C. Attention-deficit/hyperactivity disorder in pregnancy and the postpartum period. Am J Obstet Gynecol. 2024 Jul;231(1):19-35. doi: 10.1016/j.ajog.2024.02.297. Epub 2024 Mar 1. PMID: 38432409.
* Oliva HNP, Prudente TP, Mayerson TF, Mignosa MM, Oliva IO, Potenza MN, Jegede OO, Angarita GA. Safety of Stimulants Across Patient Populations: A Meta-Analysis. JAMA Netw Open. 2025 May 1;8(5):e259492. doi: 10.1001/jamanetworkopen.2025.9492. Epub 2025 May 1. PMID: 40343695; PMCID: PMC12065045.
* Drugs for ADHD. Med Lett Drugs Ther. 2025 Sep 1;67(1736):137-144. doi: 10.58347/tml.2025.1736a. PMID: 40839413.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.